English Abstract
Journal Article
Research Support, Non-U.S. Gov't
Add like
Add dislike
Add to saved papers

[Inhibitory effect of antisense oligonucleotide of integrin-linked kinase on cell proliferation of human epithelial ovarian cancer].

OBJECTIVE: To explore the inhibitory effect of integrin-linked kinase antisense oligonucleotide (ILK-ASODN) on cell proliferation in human ovarian cancer cell line (HO8910).

METHODS: We transfected ILK-ASODN into HO8910 to block ILK gene expression, measured the expression levels of integrin-linked kinase (ILK) mRNA by RT-PCR and ILK protein by western-blotting; the inhibiting effects of the transfection on HO8910 proliferation, the cell cycles, and cell apoptosis were assessed by water soluble tetrazolium-1 (WST-1) and flow cytometry (FCM).

RESULTS: After transfection of ILK-ASODN, the expression levels of ILK mRNA decreased significantly in groups D, E, F being 0.307 +/- 0.011, 0.198 +/- 0.008, 0, respectively, when compared with those of the two control groups of A and B (P < 0.05). The expression levels of ILK protein of the groups D, E and F decreased significantly also, being 26.3 +/- 0.8, 20.6 +/- 0.4 and 0, respectively. HO8910 cell proliferation was inhibited significantly, and the rates of apoptosis of the groups D, E and F increased significantly, being 7.31%, 8.84% and 11.27% respectively. The cell population increased in G0/G1 phase of the groups D, E and F, being 49.25%, 56.28% and 67.61% respectively, significantly different in comparison with those of groups of A and B (P < 0.01).

CONCLUSIONS: Transfection of ILK-ASODN into human ovarian cancer line inhibited cancer cell proliferation significantly.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app